Hibor

Hibor is a subcutaneous injection that contains the low molecular weight heparin bemiparin sodium; the product is supplied in an unspecified strength and is marketed in the European Union as a prescription‑only anticoagulant. It belongs to the therapeutic class of anticoagulants and works by enhancing antithrombin III activity. Hibor is administered under medical supervision to help prevent and treat thrombotic conditions in patients at risk.

Hibor is indicated for several clinical situations where inhibition of clot formation is required.

- Prevention of venous thromboembolism (VTE) in patients undergoing orthopedic surgery such as hip or knee replacement. - Treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE). - Prophylaxis of thromboembolic events in patients with limited mobility after major abdominal or pelvic surgery. - Use in patients with a high risk of postoperative clotting when mechanical methods are insufficient. - Management of clotting risk in certain medical conditions where anticoagulation is recommended.

Like other anticoagulants, bemiparin sodium may be associated with adverse reactions that range from mild to severe.

Common: - Injection site reactions such as erythema, pain, induration, or localized swelling. - Minor bleeding events including epistaxis, gum bleeding, bruising, or mild gastrointestinal bleeding. - Gastrointestinal discomfort or nausea. - Transient elevation of liver enzymes. - Localized warmth at the injection site.

Serious: - Major hemorrhage, including intracranial or gastrointestinal bleeding. - Expanding hematoma at the injection site. - Thrombocytopenia, especially heparin‑induced thrombocytopenia (HIT). - Allergic reactions such as urticaria, angioedema, or anaphylaxis. - Spontaneous bleeding from mucosal surfaces. - Severe systemic allergic response leading to anaphylactic shock.

Before initiating therapy with Hibor, clinicians should evaluate patient-specific factors that may increase the risk of bleeding or other complications.

- Known hypersensitivity to bemiparin sodium or any component of the formulation. - Active major bleeding or a high risk of uncontrolled hemorrhage. - Severe renal impairment (creatinine clearance <30 mL/min) because clearance of low molecular weight heparins is reduced. - Concomitant use of other anticoagulants, antiplatelet agents, or thrombolytics. - Pregnancy and breastfeeding status, as safety data are limited. - History of heparin‑induced thrombocytopenia (HIT). - Planned neuraxial anesthesia or spinal puncture, which requires careful timing.

Bemiparin sodium can interact with several medicines, potentially altering its anticoagulant effect or increasing bleeding risk.

Avoid: - Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) or high‑dose antiplatelet drugs. - Systemic thrombolytic agents such as alteplase or streptokinase.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) and aspirin, which may increase minor bleeding. - Selective serotonin reuptake inhibitors (SSRIs) or other drugs affecting platelet function. - Medications that impair renal function, potentially reducing bemiparin clearance. - Herbal supplements with anticoagulant properties, such as ginkgo biloba or garlic.